Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12494/13905
Exportar a:
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorQuirós Arango, Héctor Manuel-
dc.creatorEspinal Correa, Claudia Elena-
dc.creatorÁlvarez Florez, Claudia Marcela-
dc.creatorRestrepo Carmona, Jaime Alonso-
dc.creatorPalacios Barahona, Arlex Uriel-
dc.creatorRestrepo Montoya, Héctor Mario-
dc.creatorLizcano Cardona, Douglas-
dc.creatorSuárez Osorio, Isabel Cristina-
dc.creatorLópez Zapata, Faber-
dc.date.accessioned2019-09-16T20:24:23Z-
dc.date.available2019-09-16T20:24:23Z-
dc.date.issued2011-
dc.identifier.urihttp://hdl.handle.net/20.500.12494/13905-
dc.format.extent13 p.es
dc.publisherUniversidad Cooperativa de Colombia, Facultad de Ciencias Económicas, Administrativas y Contables, Especialización en Gerencia de la Calidad y Auditoria en Salud, Medellín y Envigadoes
dc.subjectAnticuerposes
dc.subjectVacunaciónes
dc.subjectNeoplasias del cuello uterinoes
dc.subjectVirus del papiloma humano (VPH)es
dc.title“Evaluación de anticuerpos anti-HPV16 y anti-HPV18 en mucosa vaginal frente a la vacunación contra el Papiloma Virus Humano en mujeres entre los 18 y 55 años en Antioquia”es
dc.typeTrabajos de grado - Posgradoses
dc.rights.licenseAtribuciónes
dc.publisher.departmentMedellínes
dc.publisher.programEspecialización en Gerencia de la Calidad y Auditoría en Saludes
dc.identifier.bibliographicCitationEspinal Correa, C. E., Álvarez Florez, C. M., Restrepo Carmona, J. A., Palacios Barahona, A. U., Restrepo Montoya, H. M., Lizcano Cardona, D., Suárez Osorio, I. C. y López Zapata, F. (2011). “Evaluación de anticuerpos anti-HPV16 y anti-HPV18 en mucosa vaginal frente a la vacunación contra el Papiloma Virus Humano en mujeres entre los 18 y 55 años en Antioquia” (Tesis de posgrado). Universidad Cooperativa de Colombia, Medellín. Recuperado de http://hdl.handle.net/20.500.12494/13905es
dc.rights.accessRightsrestrictedAccesses
dc.source.bibliographicCitationOrganización Panamericana de la Salud. Planificación de programas apropiados para la prevención del cáncer cervicouterino. Programa para una tecnología apropiada en salud. En: http://ncd.bvsalud.org/lildbi/docsonline/1/3/031planificacion_de_programas_prevencion.pdfes
dc.source.bibliographicCitationLewis, Merle J. A Situational Analysis of Cervical Cancer in Latin America and the Caribbean. Washington, DC: Pan American Health Organization / World Health Organization (PAHO/WHO), 2004.es
dc.source.bibliographicCitationInstituto Nacional de Cancerología. Anuario Estadístico 2009. 2009;7:32.es
dc.source.bibliographicCitationSyrjänen KJ, Pyrhönen S. Demonstration of human papilloma virus antigen in the condylomatous lesions of the uterine cervix by immunoperoxidase technique. Gynecol Obstet Invest. 1982;14(2):90-6.es
dc.source.bibliographicCitationPilotti S, Rilke F, Alasio L, Fontanelli R. Histologic evidence for an association of cervical intraepithelial neoplasia with human papilloma virus infection. Diagn Gynecol Obstet. 1982;4(4):357-62.es
dc.source.bibliographicCitationMurillo R, Molano M, Martínez G, Mejía J, Gamboa O. HPV Prevalence in Colombian Women with Cervical Cancer: implications for vaccination in a Developing Country. Infect Dis Obstet Gynecol. 2009; 2009: 653598.es
dc.source.bibliographicCitationBray F, Loos AH, McCarron P, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005;14:677–86.es
dc.source.bibliographicCitationHristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol 1997;36 Suppl 9:1–60.es
dc.source.bibliographicCitationChoi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine. 2010;28(24):4091-102.es
dc.source.bibliographicCitationGauthier A, Martín-Escudero V, Moore L, Ferko N, de Sanjosé S, Pérez-Escolano I, et al. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain. Eur J Public Health. 2008;18(6):674-80.es
dc.source.bibliographicCitationPedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40(6):564-71.es
dc.source.bibliographicCitationHickey DK, Patel MV, Fahey JV, Wira CR. Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol. 2011;88(2):185-94.es
dc.source.bibliographicCitationJoura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernández-Ávila M, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008;26(52):6844-51.es
dc.source.bibliographicCitationKemp TJ, García-Piñeres A, Falk RT, Poncelet S, Dessy F, Giannini SL, et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 26 (2008) 3608–3616.es
dc.source.bibliographicCitationHarper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364(9447):1757–65.es
dc.source.bibliographicCitationHarper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Webappendix. En: http://image.thelancet.com/extras/04art10103webappendix.pdfes
dc.source.bibliographicCitationCastle PE, Rodriguez AC, Bowman FP, Herrero R, Schiffman M, Bratti MC, et al. Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions. Clin Diagn Lab Immunol. 2004 Mar;11(2):399-405.es
dc.source.bibliographicCitationSuzich ja, ghim s-j, palmer hillfj, white wi, tamura jk, bell ja, et al. Systemic immunization whit papillomavirusl1 pprotein completely prevents the development of viral mucosal papillomas. Proc natl acad sci usa 1995, 92(25):11553-7.es
dc.source.bibliographicCitationGiannini sl, hanon e, moris p, van mechelen m, morel s, dessy f, et al. Enhanced humoral and memory c cellular immunity using phv 16/18 l1 vlp vaccine formulated whit the mlp/aluminium salt combination (aso4) compared to aluminium salt only. Vaccine 2006; 24 (33-34):5937-es
dc.source.bibliographicCitationPederssen c, petaja t, straussg, rumke hc, podera, richardus jh, et al. Immunization of early adolescent females whit human papillomavirus type 16 and 18 virus-like particle vaccine containing aso4 adjuvant. J adolescent health 2007; 40(6):564-71.es
dc.source.bibliographicCitationSchwartz tf, dubin g, on behalf og the hpv vaccine study investigators for adults women . Human papillomavirus (hpv) 16/18 l1 aso4 virus like- particle (vlp) cervical cáncer vaccine is inmmunogenic and well-tolerated 18 months after vaccination in womens up to age years. American society of clinical oncology annual meeting, chicago, usa , jun 1-5, 2007.es
Appears in Collections:Gerencia de la Calidad y Auditoría en Salud

Files in This Item:
File Description SizeFormat 
2011_evaluación_anticuerpos_antihpv.pdfTrabajo de grado394.76 kBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.